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Case Report
Refractory gastric ulcer due to undisclosed use of topical
diclofenac epolamine patches
Yuta Oda, Hiromichi Naito, Tsuyoshi Nojima, and Atsunori Nakao
Dentistry and Pharmaceutical Sciences, Department of Emergency, Critical Care, and Disaster Medicine,
Okayama University Graduate School of Medicine, Okayama, Japan
Background: Topical forms of nonsteroidal anti-inflammatory drugs (NSAIDs) have been created to lessen systemic adverse
effects. In general, they are believed to be well tolerated and appropriate for use as an over-the-counter (OTC) drug.
Case Presentation: A 68-year-old woman visited our clinic due to tarry stool. The patient reported multiple episodes of recurrent
bleeding from a gastric ulcer for 2 months and was treated with endoscopic hemostatic clipping. The patient disclosed she had been
using a large number of diclofenac patches for more than 3 months. The patient was treated conservatively by discontinuation of di-
clofenac patches and treatment with a proton pump inhibitor and omeprazole.
Conclusion: In conclusion, inappropriate use of topical NSAID patches can be a cause of peptic ulcer bleeding. Patients reporting
multiple episodes of recurrent bleeding from a gastric ulcer should be questioned, particularly about the use of OTC medications that
might include topical NSAID patches.
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BACKGROUND
TOPICAL FORMS OF nonsteroidal anti-inflammatorydrug (NSAIDs) have been developed to lessen systemic
adverse effects associated with oral NSAIDs, such as gas-
trointestinal injury and renal toxicity and currently are com-
monly to relieve pain from localized musculoskeletal
ailments such as epicondylitis, ankle sprains, and knee
osteoarthritis.1 In general, they are believed to be well toler-
ated and appropriate for use as an over-the-counter (OTC)
drug without a medical prescription or supervision of health-
care professionals.2
We report a case of recurrent peptic ulcer bleeding caused
by chronic excessive use of topical diclofenac epolamine
patches in an elderly female patient. Despite routine ques-
tions regarding past medications, patients might not always
accurately remember their medications, especially OTC
medications.3 The present case demonstrates that
inappropriate use of topical NSAIDs could have serious
implications, resulting in substantial morbidity and mortal-
ity, as well as increasing health-care costs.4 This report is a
reminder that patients often do not disclose the use of OTC
drugs, including NSAID patches, which can be possible
causes of unexplained refractory peptic ulcers.5
CASE PRESENTATION
A 68-year-old woman visited our clinic due to tarrystool and was admitted for urgent treatment. The patient
reported multiple episodes of recurrent bleeding from a gas-
tric ulcer for 2 months and was treated with endoscopic
hemostatic clipping. Her prescribed medicines were amlodip-
ine (5 mg/day), sennoside (12 mg/day), and omeprazole
(10 mg/day).
The patient was alert with stable vital signs: blood pres-
sure, 124/78 mmHg; heart rate, 78 b.p.m.; and body temper-
ature, 36.2°C. Laboratory test values included white blood
cell count of 1.21 9 103/ll and platelet count of
870 9 103/ll. Hemoglobin levels were reduced to 5.8 mg/
dl. Her other blood chemistry results (creatinine and blood
urea nitrogen) were within normal range. Her serum gastrin
level was 34 pg/ml (normal range, 0–180 pg/ml). Computed
tomography revealed no pneumoperitoneum or ascites in the
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abdominal cavity. Upper gastrointestinal endoscopy on the
day of admission demonstrated a large ulcer on the anterior
corpus of the stomach with diffuse pseudomembranes. Biop-
sied ulcer specimens showed ulcerated gastric mucosa with
fibrinonecrotic debris and acute inflammation, exudates, and
reactive epithelial changes. Tests for Helicobacter pylori
infection were negative. Before admission, the patient had
been going about her life as usual, with no abnormal stres-
sors. The patient disclosed she had using a large number of
diclofenac patches (20 mg 9 eight sheets together in a day)
for more than 3 months to ameliorate pain in her back and
shoulder. The use of an excessive number of diclofenac
patches was a potential cause of her gastric ulcer. The patient
was treated conservatively by discontinuation of diclofenac
patches and treatment with a proton pump inhibitor and
omeprazole. Repeated gastroendoscopy performed 7 days
later showed that her ulcers previously bleeding were heal-
ing, but had a largely improved endoscopic appearance.
DISCUSSION
TOPICALLYAPPLIED NSAIDS provide the benefits ofenhanced delivery of local drugs to affected tissues and
have a superior safety profile, with lower incidence of sys-
temic adverse effects, compared with oral NSAIDs. Approxi-
mately 10%–15% of patients experience adverse effects
secondary to topical NSAID application, but these are mostly
cutaneous conditions like pruritus and rash at the application
site.2 For topical NSAIDs, skin reactions are the most fre-
quent, accounting for 95% of all events.6 Adverse gastroin-
testinal drug reactions are very rare with topical NSAIDs,
compared to 15% incidence for oral NSAIDs.2 To the best our
knowledge, only five cases of gastrointestinal bleeding due to
NSAID patches have been previously reported in Japan
(Table 1). Although critical complications are rare, topical
NSAIDs should be used carefully in patients with other risk
factors for upper gastrointestinal bleeding, including smoking,
advanced age, concomitant use of oral corticosteroids or anti-
coagulants, history of peptic ulcer, and the presence of H.
pylori infection. Sudden impairment of renal function could
occur after modest exposure to topical NSAIDs; patients with
this history should be cautioned to avoid these medications
regardless of the administration route or dose.7
As percutaneous absorption of NSAIDs could be influ-
enced by the properties of the skin, dose, and method of
administration, local tissue concentrations after topical
application of NSAIDs are highly variable. However,
overall concentrations in tissues including the tendons,
muscles, and subcutis after topical NSAID application are
regularly several times higher than those observed after
oral intake.8 Pharmacokinetic elimination data showed that
NSAIDs remain in the tissue locally much longer than
after oral administration, which can be explained by
the presence of a tissue reservoir.9 Topical NSAIDs are
absorbed gradually and in small amounts into the systemic
circulation; maximal plasma NSAID concentration and
bioavailability following topical application are normally
less than 5% and 15%, respectively, compared with identi-
cal oral dose.2
Our experience illustrates that undisclosed use of topical
NSAIDs could be the cause of an unexplained peptic ulcer.
We must include questions regarding nonprescription
medicines, supplements and herbals remedies. However,
undisclosed use of NSAIDs is well recognized. Patients
remember only approximately half of their medications,
and recall of OTC NSAIDs could be lower than recall of
prescription drugs.5 Surprisingly, it is estimated that
approximately 30% of patients with peptic ulcers who
denied NSAID use on interview had been found to have
taken NSAIDs based on suppressed levels of serum throm-
boxane B2.10
A limitation of this study is a lack of measurement of
plasma diclofenac or thromboxane concentrations. Although
we do not have evidence that the topical NSAID caused
Table 1. Cases of gastrointestinal bleeding due to topical nonsteroidal anti-inflammatory drug use (review of Japanese reports)
First author Year Age (years) Gender Medicine Dose/day Site of ulcer
Oda 2021 68 Female Ketoprofen 160 mg Stomach
Shirohata 2020 70s Female Diclofenac 210 mg Ileum
Kimoto 2020 63 Female Ketoprofen 160–200 mg Stomach
Aoyama 2019 70 Male Flurbiprofen 240 mg Ileum
Nagano 2017 N/A N/A Esflurbiprofen N/A Stomach
Hirose 2017 74 Male Ketoprofen 160 mg Ileum
Abbreviation: N/A, not available.
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gastric ulcer bleeding in this patient, immediate improve-
ment of the symptoms without recurrence of peptic ulcers
after discontinuation of these patches could support our
diagnosis.
In conclusion, inappropriate use of topical NSAID
patches can be a cause of peptic ulcer bleeding. Immediate
discontinuation of NSAID patches combined with proton
pump inhibitors resulted in an early recovery. Patients
should be questioned, particularly about the use of OTC




Approval of the research protocol: N/A.
Informed consent: Informed consent was obtained from the
patient to publish this case report.
Registry and registration no. of the study/trial: N/A.
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